查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1844354

快速診斷市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Rapid Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2024 年全球快速診斷市場價值為 353 億美元，預計到 2034 年將以 6.8% 的複合年成長率成長至 689 億美元。

快速診斷市場 - IMG1

市場不斷擴大，原因有很多，包括傳染病數量的增加、即時檢測的日益普及、診斷技術的不斷創新以及醫療基礎設施升級投資的穩步成長。快速診斷測試旨在在幾分鐘到幾小時內提供準確的結果，使其成為早期發現和及時醫療回應的關鍵工具。這些測試廣泛應用於診所、家庭和藥房，以支援即時醫療決策。它們使用分子診斷、免疫測定和橫向流動分析等各種平台來提供及時、可靠的結果。生物感測器、微流體技術和基於人工智慧的診斷工具的進步進一步提高了它們的速度、準確性和實用性。與數位醫療系統的更廣泛整合也支持了市場的成長，這提高了診斷效率，並擴展了感染監測以外的應用。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 353億美元
預測值 689億美元
複合年成長率 6.8%

2024年，傳染病檢測領域佔了25.2%的市場。由於全球對肝炎、愛滋病毒、結核病、瘧疾和流感等疾病的早期快速檢測需求持續高漲，該領域繼續保持領先地位。隨著全球健康風險的增加和傳播率的上升，早期診斷已成為當務之急。快速檢測在快速識別這些疾病、加速治療啟動以及降低整體死亡率方面發揮關鍵作用。

2024年，非處方藥 (OTC) 診斷市場規模達231億美元，預計到2034年將以7.1%的複合年成長率成長。消費者越來越重視個人健康管理，這推動了對自測劑盒的需求。數位健康資源的便捷獲取以及家用診斷產品的市場推廣，顯著提升了人們對使用OTC試劑盒的信心。人們正在利用這些工具進行血糖水平、懷孕和感染等健康狀況的常規監測。

2024年，美國快速診斷市場規模達168億美元。這一成長得益於北美地區強大的醫療基礎設施、先進的實驗室和廣泛的醫院網路。這些因素為尖端診斷技術的快速應用奠定了堅實的基礎。高效的實驗室系統也有助於快速部署和擴展診斷工具，從而促進該地區快速檢測的普及。

塑造全球快速診斷市場競爭格局的知名公司包括 Trinity Biotech、雅培、Quidel、賽默飛世爾科技、羅氏、Sight Diagnostics、ACON、BIOMERIEUX、Alfa Scientific、Meridian Bioscience、Becton、Dickinson and Company (BD)、QIAGEN、雅昌、Hologic、Becton、Dickinson and Company (BD)、QIAGEN、雅昌、Hologic、BIO-Ho層。為了獲得更強大的市場地位，快速診斷產業的公司正在積極推行以技術創新和全球影響力為重點的策略。許多公司正在投入大量資金進行研發，以打造高度準確、快速且方便用戶使用的檢測試劑盒。與醫療保健提供者和分銷合作夥伴的策略合作使這些公司能夠拓展新興市場。此外，公司正在採用數位整合和人工智慧驅動的平台來增強檢測解讀和結果管理。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 傳染病的盛行率不斷上升
      • 技術進步
      • 快速診斷測試日益普及
      • 提高人們對早期診斷的認知
      • 政府加強對傳染病診斷的力度
    • 產業陷阱與挑戰
      • 結果準確度低
      • 替代產品的可用性
      • 嚴格的監管框架
    • 市場機會
      • 向新興市場和分散照護端擴張
      • 與遠距醫療和數位報告的整合
  • 成長潛力分析
  • 報銷場景
  • 監管格局
    • 北美洲
    • 歐洲
    • 亞太地區
  • 技術格局
    • 當前的技術趨勢
    • 新興技術
  • 差距分析
  • 波特的分析
  • PESTEL分析
  • 價值鏈分析
  • 未來市場趨勢

第4章：競爭格局

  • 介紹
  • 公司矩陣分析
  • 公司市佔率分析
    • 全球的
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲和中東地區
  • 競爭定位矩陣
  • 主要市場參與者的競爭分析
  • 關鍵進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 擴張計劃

第5章：市場估計與預測：按產品，2021 - 2034 年

  • 主要趨勢
  • 傳染病檢測
    • 呼吸道感染檢測產品
    • 流感
    • 肝炎
    • 愛滋病
    • 其他傳染病檢測
  • 妊娠和生育能力測試
  • 血液學檢測產品
  • 血糖監測
  • 藥物濫用（DoA）檢測產品
  • 心臟代謝測試
  • 凝血檢測產品
  • 膽固醇檢測產品
  • 尿液分析檢測產品
  • 腫瘤/癌症標記檢測產品
  • 糞便隱血檢測產品
  • 其他產品

第6章：市場估計與預測：按購買量，2021 - 2034 年

  • 主要趨勢
  • OTC 測試
  • 基於處方的測試

第7章：市場估計與預測：按技術/平台，2021 - 2034 年

  • 主要趨勢
  • 流通式
  • 固相
  • 橫向流動
  • 凝集試驗
  • 其他技術/平台

第 8 章：市場估計與預測：按配銷通路，2021 年至 2034 年

  • 主要趨勢
  • 實體店面
  • 電子商務

第9章：市場估計與預測：依最終用途，2021 - 2034

  • 主要趨勢
  • 醫院和診所
  • 診斷中心
  • 居家照護環境
  • 其他最終用途

第 10 章：市場估計與預測：按地區，2021 年至 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：公司簡介

  • Abbott
  • ACON
  • Alfa Scientific
  • Artron
  • Becton, Dickinson and Company (BD)
  • BIOMERIEUX
  • BIO-RAD
  • Danaher
  • HOLOGIC
  • Meridian Bioscience
  • QIAGEN
  • Quidel
  • Roche
  • Sight Diagnostics
  • Thermo Fisher Scientific
  • Trinity Biotech
簡介目錄
Product Code: 5745

The Global Rapid Diagnostics Market was valued at USD 35.3 billion in 2024 and is estimated to grow at a CAGR of 6.8% to reach USD 68.9 billion by 2034.

Rapid Diagnostics Market - IMG1

The market is expanding due to several factors, including the rising number of infectious diseases, the increasing popularity of point-of-care testing, continuous innovation in diagnostic technologies, and the steady rise in investments aimed at upgrading healthcare infrastructure. Rapid diagnostic tests are designed to deliver accurate results within minutes to a few hours, making them a crucial tool for early detection and prompt medical response. These tests are widely used in clinics, homes, and pharmacies to support real-time healthcare decisions. They use a variety of platforms such as molecular diagnostics, immunoassays, and lateral flow assays to provide timely, dependable results. Advancements in biosensors, microfluidic technology, and AI-based diagnostic tools have further enhanced their speed, accuracy, and utility. Market growth is also supported by broader integration with digital health systems, improving diagnostic efficiency and expanding applications beyond just infection monitoring.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$35.3 Billion
Forecast Value$68.9 Billion
CAGR6.8%

The infectious disease testing segment held a 25.2% share in 2024. The segment continues to lead as the demand for early and rapid detection of illnesses like hepatitis, HIV, tuberculosis, malaria, and influenza remains high worldwide. With growing global health risks and higher transmission rates, early diagnosis has become a top priority. Rapid tests play a key role in identifying these diseases quickly, enabling faster treatment initiation and helping reduce the overall mortality rate.

In 2024, the over-the-counter (OTC) diagnostics segment generated USD 23.1 billion, and it is expected to grow at a CAGR of 7.1% through 2034. Consumers are increasingly prioritizing personal health management, which fuels demand for self-testing kits. The ease of access to digital health resources and marketing efforts promoting home-use diagnostics has significantly increased confidence in using OTC kits. People are embracing these tools for routine monitoring of health conditions like glucose levels, pregnancy, and infections.

U.S. Rapid Diagnostics Market generated USD 16.8 billion in 2024. This growth is supported by the presence of a robust healthcare infrastructure, advanced laboratories, and wide hospital networks across North America. These factors have created a solid foundation for the rapid adoption of cutting-edge diagnostic technologies. Efficient lab systems also allow for quick rollout and scaling of diagnostic tools, contributing to the strong uptake of rapid testing in the region.

Notable companies shaping the competitive landscape of the Global Rapid Diagnostics Market include Trinity Biotech, Abbott, Quidel, Thermo Fisher Scientific, Roche, Sight Diagnostics, ACON, BIOMERIEUX, Alfa Scientific, Meridian Bioscience, Becton, Dickinson and Company (BD), QIAGEN, Artron, Hologic, BIO-RAD, and Danaher. To gain a stronger position, companies within the rapid diagnostics industry are pursuing aggressive strategies focused on technological innovation and global reach. Many are channeling significant investment into research and development to create highly accurate, faster, and user-friendly test kits. Strategic collaborations with healthcare providers and distribution partners allow these firms to expand into emerging markets. Additionally, firms are adopting digital integration and AI-driven platforms to enhance test interpretation and result management.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Purchase trends
    • 2.2.4 Technology/platform trends
    • 2.2.5 Distribution channel trends
    • 2.2.6 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of infectious disease
      • 3.2.1.2 Technological advancements
      • 3.2.1.3 Growing popularity of rapid diagnostic tests
      • 3.2.1.4 Rising awareness regarding early diagnosis among people
      • 3.2.1.5 Increasing government initiatives for the diagnosis of infectious diseases
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Low accuracy of results
      • 3.2.2.2 Availability of substitute products
      • 3.2.2.3 Stringent regulatory framework
    • 3.2.3 Market opportunities
      • 3.2.3.1 Expansion into emerging markets and decentralized care sites
      • 3.2.3.2 Integration with telemedicine and digital reporting
  • 3.3 Growth potential analysis
  • 3.4 Reimbursement scenario
  • 3.5 Regulatory landscape
    • 3.5.1 North America
    • 3.5.2 Europe
    • 3.5.3 Asia Pacific
  • 3.6 Technology landscape
    • 3.6.1 Current technological trends
    • 3.6.2 Emerging technologies
  • 3.7 Gap analysis
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis
  • 3.10 Value chain analysis
  • 3.11 Future market trends

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
    • 4.3.4 Asia Pacific
    • 4.3.5 LAMEA
  • 4.4 Competitive positioning matrix
  • 4.5 Competitive analysis of major market players
  • 4.6 Key developments
    • 4.6.1 Mergers and acquisitions
    • 4.6.2 Partnerships and collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Infectious disease testing
    • 5.2.1 Respiratory infection testing products
    • 5.2.2 Influenza
    • 5.2.3 Hepatitis
    • 5.2.4 HIV
    • 5.2.5 Other infectious disease testings
  • 5.3 Pregnancy and fertility testing
  • 5.4 Hematology testing products
  • 5.5 Glucose monitoring
  • 5.6 Drug-of-abuse (DoA) testing products
  • 5.7 Cardiometabolic testing
  • 5.8 Coagulation testing products
  • 5.9 Cholesterol testing products
  • 5.10 Urinalysis testing products
  • 5.11 Tumor/cancer marker testing products
  • 5.12 Fecal occult testing products
  • 5.13 Other products

Chapter 6 Market Estimates and Forecast, By Purchase, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 OTC tests
  • 6.3 Prescription-based tests

Chapter 7 Market Estimates and Forecast, By Technology/Platform, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Flow-through
  • 7.3 Solid phase
  • 7.4 Lateral flow
  • 7.5 Agglutination assays
  • 7.6 Other technology/platforms

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Brick and mortar
  • 8.3 E-commerce

Chapter 9 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospitals & clinics
  • 9.3 Diagnostic centers
  • 9.4 Homecare settings
  • 9.5 Other end use

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE

Chapter 11 Company Profiles

  • 11.1 Abbott
  • 11.2 ACON
  • 11.3 Alfa Scientific
  • 11.4 Artron
  • 11.5 Becton, Dickinson and Company (BD)
  • 11.6 BIOMERIEUX
  • 11.7 BIO-RAD
  • 11.8 Danaher
  • 11.9 HOLOGIC
  • 11.10 Meridian Bioscience
  • 11.11 QIAGEN
  • 11.12 Quidel
  • 11.13 Roche
  • 11.14 Sight Diagnostics
  • 11.15 Thermo Fisher Scientific
  • 11.16 Trinity Biotech